Heated thread.
Russ, I was talking the same terms you were. You mention a 'loan' in the post I responded to and used the same terminology.
DV, I have mention previous what I think mgt should do. I mentioned this well before this announcement and my views haven't changed. Have a read. Essentially less spending on US sales to preserve cash til vax results. See how organic growth for cardiocel sales in the US go with the massive spending on sales.
I'm not a downramper. I own plenty of stock but think mgt could do a better job. I think the product is great but decisions being made are, imo, not in the best interest of current shareholders.
My error on the Dr comment as Julian is the COO (not CFO).
Ann: Trading Halt, page-228
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.800(6.06%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $13.08 | $14.00 | $12.84 | $202.5K | 15.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 88 | $13.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1109 | 2 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |